NCT06027333 Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease
| NCT ID | NCT06027333 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Berner Reha Zentrum AG |
| Condition | Interstitial Lung Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-11-08 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2023-11-08 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with fibrotic insterstitial lung disease (ILD) participating in inpatient rehabilitation or in outpatient pulmonary care will be invited to participate in this observational study. Patients will fill out questionnaire regarding quality of life and symptoms at baseline and follow-up (at the end of rehabilitation or after the second outpatient ILD consultation). Additionally, clinical data obtained in clinical routine or for the IIP registry will be used for this project. The aim is to assess changes in self-efficacy and quality of life over time and to establish a control cohort for a later feasibility study on a educational and self-management intervention (currently in planning).
Eligibility Criteria
Inclusion criteria are: * For Berner Reha Zentrum only: Diagnosis of a FILD as major indication for pulmonary rehabilitation * For Inselspital only: Enrolled in Idiopathic interstitial Pneumonia (IIP) cohort study (Nr. 246/15 / PB\_2016-01524) and agreed to further use of data for further research purpose * Age ≥ 18 years * Written informed consent Exclusion criteria are: * Cognitive inability or insufficient knowledge of project language (German) to follow informed consent or study procedures * Sarcoidosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06027333 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06027333 currently recruiting?
Yes, NCT06027333 is actively recruiting participants. Contact the research team at t.marcin@rehabern.ch for enrollment information.
Where is the NCT06027333 trial being conducted?
This trial is being conducted at Bern, Switzerland, Bern, Switzerland.
Who is sponsoring the NCT06027333 clinical trial?
NCT06027333 is sponsored by Berner Reha Zentrum AG. The trial plans to enroll 80 participants.